Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Tingbo Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0143-3353; OpenAlex author ID A5101490899, A5109294101, A5115590360. Sources: ClinicalTrials.gov.

Their work

Papers
79 (first author 0, last author 52)
Trials
6 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
152
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 3 papers · 2018: 3 papers, 3 trials · 2019: 7 papers, 1 trial · 2020: 9 papers · 2021: 5 papers · 2022: 8 papers, 1 trial · 2023: 15 papers · 2024: 8 papers, 1 trial · 2025: 8 papers · 2026: 6 papers

Papers 50 of 79

  1. Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer. Co-author DOI 10.1002/advs.76135↗
  2. Loss of PBRM1 accelerates pancreatic cancer progression by inducing acquisition of mesenchymal phenotype and inflammatory cancer-associated fibroblasts reprogr… Last author DOI 10.1016/j.canlet.2026.218797↗
  3. MG53 suppresses IRF7 to reprogram macrophages and promote antitumor immunity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.118000↗
  4. Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer: A Retrospectively Observa… Last author DOI 10.1097/sla.0000000000006600↗
  5. MTFP1 drives pancreatic cancer liver metastatic colonisation by regulating mitochondrial metabolism reprogramming. Last author DOI 10.1136/gutjnl-2025-336323↗
  6. Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer. Co-author DOI 10.1186/s40164-026-00818-9↗
  7. Bacteria and tumor debris induced pancreatic cancer progression via the NF-κB signaling pathway. Last author DOI 10.1016/j.canlet.2025.217964↗
  8. Nano-enabled repurposing of Benproperine phosphate enhances pancreatic Cancer chemotherapy through lethal autophagy arrest and immune activation. Co-author DOI 10.1016/j.jconrel.2025.114187↗
  9. Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-associated fibroblasts. Co-author DOI 10.1016/j.ymthe.2025.01.023↗
  10. A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41388-025-03567-x↗
  11. IRE1α translational suppression potentiates STING-dependent chemoresistance in pancreatic cancer. Last author DOI 10.1038/s41419-025-07999-x↗
  12. Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63146-2↗
  13. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci187024↗
  14. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. Co-author DOI 10.1186/s13046-025-03323-9↗
  15. Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. Co-author DOI 10.1002/advs.202401845↗
  16. Deciphering extracellular vesicles protein cargo in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2024.189142↗
  17. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2024.216607↗
  18. IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Last author DOI 10.1016/j.celrep.2024.114088↗
  19. Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.xcrm.2024.101731↗
  20. Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance. Last author DOI 10.1080/15548627.2023.2300913↗
  21. Cell of Origin of Pancreatic cancer: Novel Findings and Current Understanding. Last author DOI 10.1097/mpa.0000000000002301↗
  22. 18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma. Last author DOI 10.2967/jnumed.123.266283↗
  23. VG161 activates systemic antitumor immunity in pancreatic cancer models as a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Last author DOI 10.1002/jmv.28108↗
  24. Multi-omics analysis reveals the chemoresistance mechanism of proliferating tissue-resident macrophages in PDAC via metabolic adaptation. Co-author DOI 10.1016/j.celrep.2023.112620↗
  25. Protocol for isolating single cells from human pancreatic cancer tissues and analyzing major immune cell populations using flow cytometry. Co-author DOI 10.1016/j.xpro.2023.102679↗
  26. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Co-author DOI 10.1016/j.ymthe.2023.07.021↗
  27. Targeting MFAP5 in cancer-associated fibroblasts sensitizes pancreatic cancer to PD-L1-based immunochemotherapy via remodeling the matrix. Co-author DOI 10.1038/s41388-023-02711-9↗
  28. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Co-author DOI 10.1038/s41418-022-01102-z↗
  29. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Last author DOI 10.1038/s41467-023-38578-3↗
  30. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Co-author DOI 10.1038/s41591-023-02640-w↗
  31. Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cas… Co-author DOI 10.1097/sla.0000000000005797↗
  32. Siamese Delta Network with Multimodality Fusion for Systemic Treatment Response Prediction in Pancreatic Cancer. Co-author DOI 10.1109/embc40787.2023.10340012↗
  33. Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone… Last author DOI 10.1186/s12885-023-10529-7↗
  34. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Last author DOI 10.1245/s10434-023-13383-w↗
  35. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Last author DOI 10.2217/imt-2021-0075↗
  36. Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Last author DOI 10.3389/fonc.2023.1118633↗
  37. Immune Checkpoint Neuropilins as Novel Biomarkers and Therapeutic Targets for Pancreatic Cancer. Last author DOI 10.3390/cancers15082225↗
  38. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. Last author DOI 10.1016/j.ebiom.2022.103958↗
  39. Subtyping for pancreatic cancer precision therapy. Last author DOI 10.1016/j.tips.2022.03.005↗
  40. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. Last author DOI 10.1136/jitc-2021-004129↗
  41. Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Last author DOI 10.1186/s12885-022-09974-7↗
  42. Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy. Last author DOI 10.1186/s12951-022-01282-3↗
  43. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Co-author DOI 10.1186/s13046-022-02273-w↗
  44. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Last author DOI 10.1186/s40779-022-00416-w↗
  45. MiR-519a/522-5p from pancreatic cancer-secreted exosomes promotes tumor invasion by enhancing Warburg effect Last author DOI 10.21203/rs.3.rs-1540878/v2↗
  46. Regulator of calcineurin 1 gene isoform 4 in pancreatic ductal adenocarcinoma regulates the progression of tumor cells. Last author DOI 10.1038/s41388-021-01763-z↗
  47. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Last author DOI 10.1038/s41467-021-24769-3↗
  48. Identification of 2 Chinese Primary Pancreatic Ductal Adenocarcinoma Cancer Cell Lines and Their Phenotypes. Last author DOI 10.1097/mpa.0000000000001932↗
  49. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Last author DOI 10.1186/s12943-021-01310-0↗
  50. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. Last author DOI 10.1186/s13046-021-02055-w↗

Trials 6

  1. Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer Principal investigator NCT06572813↗
  2. Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas Study chair NCT05433935↗
  3. A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma Principal investigator NCT05547074↗
  4. Chyle Leak After Pancreatic Operation Study chair NCT03127150↗
  5. A Study in Postoperative Pancreatic Fistula Study chair NCT03129607↗
  6. SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients Principal investigator NCT03716596↗

Closest collaborators

The 25 strongest of 152 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xueli Bai · 38 shared papers, 2014–2026 · strength 5.75
  2. Qi Zhang · 18 shared papers, 2015–2026 · strength 2.65
  3. Xiaozhen Zhang · 14 shared papers, 2019–2026 · strength 2.22
  4. Xing Huang · 11 shared papers, 2020–2025 · strength 2.14
  5. Lihong He · 9 shared papers, 2023–2026 · strength 1.63
  6. Mengyi Lao · 10 shared papers, 2020–2025 · strength 1.48
  7. Hanshen Yang · 9 shared papers, 2021–2025 · strength 1.48
  8. Gang Zhang · 7 shared papers, 2021–2023 · strength 1.34
  9. Tianyu Tang · 8 shared papers, 2020–2023 · strength 1.21
  10. Kang Sun · 7 shared papers, 2023–2025 · strength 1.15
  11. Jiaqi Yang · 8 shared papers, 2015–2025 · strength 1.03
  12. Risheng Que · 10 shared papers, 2016–2023 · strength 1.00
  13. Jian Xu · 6 shared papers, 2021–2024 · strength 0.94
  14. Yifan Hong · 4 shared papers, 2023–2025 · strength 0.84
  15. Xueli Bai · 9 shared papers, 2015–2020 · strength 0.84
  16. Lingyue Liu · 4 shared papers, 2022–2026 · strength 0.80
  17. Qihan Fu · 7 shared papers, 2016–2023 · strength 0.79
  18. Zhengtao Hong · 4 shared papers, 2022–2025 · strength 0.76
  19. Xiang Li · 7 shared papers, 2019–2023 · strength 0.73
  20. Tao Wei · 7 shared papers, 2017–2024 · strength 0.71
  21. Tao Ma · 8 shared papers, 2018–2021 · strength 0.71
  22. Xinyuan Liu · 3 shared papers, 2024–2025 · strength 0.70
  23. Jinyuan Song · 4 shared papers, 2022–2025 · strength 0.69
  24. Xiao Zhi · 7 shared papers, 2014–2025 · strength 0.66
  25. Yinan Shen · 6 shared papers, 2017–2023 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.